Exicure to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Exicure, Inc. (NASDAQ: XCUR), a biotechnology company, announced its participation in key investor conferences for September 2021. The events include Citi’s 16th Annual Biopharma Conference from September 8-10, the H.C. Wainwright 23rd Annual Global Investment Conference with a presentation on September 13 at 7:00 AM ET, and the Baird Global Healthcare Conference on September 14 at 9:40 AM ET. The company is focused on developing therapeutics using its Spherical Nucleic Acid technology, with candidates targeting Friedreich’s ataxia and advanced solid tumors.

CHICAGO, & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Exicure, Inc.^® (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced participation in the following investor conferences during the month of September:

Citi’s 16th Annual Biopharma Conference 2021
One-on-one meetings
September 8-10, 2021

H.C. Wainwright 23^rd Annual Global Investment Conference
Presentation Time: 7:00 AM ET
Virtual webcast here
Monday, September 13, 2021

Baird Global Healthcare Conference
Presentation Time: 9:40 AM ET
Tuesday, September 14, 2021

Replays of the H.C. Wainwright webcast will be available on Exicure’s website for 30 days following the event.

About Exicure, Inc.
Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for neurology, immuno-oncology, inflammatory diseases and other genetic disorders based on its proprietary Spherical Nucleic Acid, or SNA technology. Exicure believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. Exicure is in preclinical development of XCUR-FXN a lipid-nanoparticle SNA–based therapeutic candidate, for the intrathecal treatment of Friedreich’s ataxia (FA). Exicure’s therapeutic candidate cavrotolimod (AST-008) is in a Phase 1b/2 clinical trial in patients with advanced solid tumors. Exicure is based in Chicago, IL and in Cambridge, MA.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210901005158/en/

Media Contact:

Karen Sharma

MacDougall

781-235-3060

ksharma@macbiocom.com

Source: Exicure, Inc.

FAQ

What investor conferences is Exicure (XCUR) participating in September 2021?

Exicure is participating in Citi’s 16th Annual Biopharma Conference, H.C. Wainwright 23rd Annual Global Investment Conference, and Baird Global Healthcare Conference.

When is the H.C. Wainwright conference presentation by Exicure (XCUR)?

Exicure's presentation at the H.C. Wainwright conference is on September 13, 2021, at 7:00 AM ET.

What is Exicure (XCUR) focusing on with its drug development?

Exicure is developing therapeutics targeting neurology, immuno-oncology, and inflammatory diseases using its Spherical Nucleic Acid technology.

Is Exicure (XCUR) involved in any clinical trials?

Yes, Exicure's cavrotolimod is in a Phase 1b/2 clinical trial for patients with advanced solid tumors.

What is the significance of Spherical Nucleic Acid technology for Exicure (XCUR)?

Spherical Nucleic Acid technology provides unique chemical and biological advantages for targeting diseases not typically addressed by other therapeutics.